201 related articles for article (PubMed ID: 23266049)
1. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Jin Y; Ye X; Shao L; Lin BC; He CX; Zhang BB; Zhang YP
Eur J Cancer; 2013 May; 49(7):1619-26. PubMed ID: 23266049
[TBL] [Abstract][Full Text] [Related]
2. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma.
Wan XB; Wei L; Li H; Dong M; Lin Q; Ma XK; Huang PY; Wen JY; Li X; Chen J; Ruan DY; Lin ZX; Chen ZH; Liu Q; Wu XY; Hong MH
Eur J Cancer; 2013 Jul; 49(10):2356-64. PubMed ID: 23541571
[TBL] [Abstract][Full Text] [Related]
3. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma.
Li G; Gao J; Tao YL; Xu BQ; Tu ZW; Liu ZG; Zeng MS; Xia YF
Chin J Cancer; 2012 Apr; 31(4):197-206. PubMed ID: 22237040
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Zhou J; Zhang WM; Chen H; Xie B; Zheng JH; Xu ZY; Lin JR
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):867-72. PubMed ID: 20137355
[TBL] [Abstract][Full Text] [Related]
5. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis.
Zhou GQ; Tang LL; Mao YP; Chen L; Li WF; Sun Y; Liu LZ; Li L; Lin AH; Ma J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e359-65. PubMed ID: 22000748
[TBL] [Abstract][Full Text] [Related]
6. The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma.
Sun P; Chen C; Xia Y; Bi X; Liu P; Zhang F; Yang H; An X; Jiang W; Wang F
Dis Markers; 2017; 2017():6570808. PubMed ID: 28676731
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Zhou GQ; Ren XY; Mao YP; Chen L; Sun Y; Liu LZ; Li L; Lin AH; Mai HQ; Ma J
Sci Rep; 2016 Mar; 6():22326. PubMed ID: 26928265
[TBL] [Abstract][Full Text] [Related]
8. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.
Chen C; Sun P; Dai QS; Weng HW; Li HP; Ye S
PLoS One; 2014; 9(11):e112581. PubMed ID: 25393117
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Serum Lactate Dehydrogenase Level as an Independent Prognostic Factor of Nasopharyngeal Carcinoma in the Intensity-Modulated Radiation Therapy Era.
Chen Z; Guo Q; Lu T; Lin S; Zong J; Zhan S; Xu L; Pan J
Med Sci Monit; 2017 Jan; 23():437-445. PubMed ID: 28120819
[TBL] [Abstract][Full Text] [Related]
10. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Turen S; Ozyar E; Altundag K; Gullu I; Atahan IL
Cancer Invest; 2007 Aug; 25(5):315-21. PubMed ID: 17661206
[TBL] [Abstract][Full Text] [Related]
11. Serum alkaline phosphatase predicts survival outcomes in patients with skeletal metastatic nasopharyngeal carcinoma.
Jin Y; Yuan MQ; Chen JQ; Zhang YP
Clinics (Sao Paulo); 2015 Apr; 70(4):264-72. PubMed ID: 26017793
[TBL] [Abstract][Full Text] [Related]
12. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy.
Cheng SH; Jian JJ; Tsai SY; Chan KY; Yen LK; Chu NM; Tan TD; Tsou MH; Huang AT
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):755-62. PubMed ID: 9652835
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Wang CT; Cao KJ; Li Y; Xie GF; Huang PY
Ai Zheng; 2007 Feb; 26(2):212-5. PubMed ID: 17298756
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors.
Zeng L; Tian YM; Huang Y; Sun XM; Wang FH; Deng XW; Han F; Lu TX
PLoS One; 2014; 9(9):e108070. PubMed ID: 25247415
[TBL] [Abstract][Full Text] [Related]
15. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
16. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Chen MY; Jiang R; Guo L; Zou X; Liu Q; Sun R; Qiu F; Xia ZJ; Huang HQ; Zhang L; Hong MH; Mai HQ; Qian CN
Chin J Cancer; 2013 Nov; 32(11):604-13. PubMed ID: 24206918
[TBL] [Abstract][Full Text] [Related]
17. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
[TBL] [Abstract][Full Text] [Related]
18. [Effect of pretreatment serum LDH and ALP levels on the prognosis of patients with nasopharyngeal carcinoma].
Zhou JY; Chen T; Li W; Ye K; Wei ZB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jul; 31(14):1069-1073. PubMed ID: 29798242
[No Abstract] [Full Text] [Related]
19. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
[TBL] [Abstract][Full Text] [Related]
20. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.
Lee AW; Tung SY; Ngan RK; Chappell R; Chua DT; Lu TX; Siu L; Tan T; Chan LK; Ng WT; Leung TW; Fu YT; Au GK; Zhao C; O'Sullivan B; Tan EH; Lau WH
Eur J Cancer; 2011 Mar; 47(5):656-66. PubMed ID: 21112774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
